Views:0 Author:Site Editor Publish Time: 2021-04-27 Origin:Site
The US Food and Drug Administration (FDA) has approved the expansion of two dosage regimens including dexamethasone (DKD) for the treatment of relapsed or refractory multiple myeloma (R / r-mm). Patients have received 1-3 courses of treatment.
In the treatment of refractory myeloma with the combination of the two drugs, their respective research results show the effectiveness of the drug.
Multiple myeloma is a hematologic cancer characterized by remission and recurrence. The prognosis of patients with each recurrence will worsen. With the increasing use of first-line immunomodulatory drugs, the number of patients receiving these drugs may increase over time. This requires effective treatment to relapse“ Despite continuous progress in the treatment of multiple myeloma, the disease is still incurable, which is particularly challenging for patients who relapse or are difficult to cure with existing treatments, "said the director of clinical research on plasma hematological malignancies; "As clinicians, choosing this option means that we can now combine two effective targeted drugs into a new non immunomodulatory triple therapy, which has proven to have a profound and lasting response in patients with relapse," said the professor of clinical medicine.
Sulfobutyl- β- Sodium cyclodextrin- β- CD) yes β- The derivative of CD has a side chain with negative charge, which has a special force on the drug with positive charge. Hydrophobic drugs can improve the water solubility of drugs, increase the absorption of drugs in human body, and improve the stability.
In addition, it can also form non covalent complexes with drug molecules, so as to improve drug safety, reduce nephrotoxicity, reduce drug hemolysis, control drug release rate and cover up unpleasant smell. SBE- β- CD has been used in injectable, oral, nasal and ophthalmic drugs with special affinity and tolerance for nitrogenous drugs.